INTERLEUKIN-2 DOSE, BLOOD MONOCYTE AND CD25+ LYMPHOCYTE COUNTS AS PREDICTORS OF CLINICAL-RESPONSE TO INTERLEUKIN-2 THERAPY IN PATIENTS WITH RENAL-CELL CARCINOMA

被引：22

作者：

HERMANN, GG ^{[1
]}

GEERTSEN, PF ^{[1
]}

VONDERMAASE, H ^{[1
]}

ZEUTHEN, J ^{[1
]}

机构：

[1] HERLEV UNIV HOSP,DEPT ONCOL,DK-2730 HERLEV,DENMARK

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1991年 / 34卷 / 02期

关键词：

RENAL CELL CARCINOMA; IL-2; RESPONSE PREDICTION; CD25+ LYMPHOCYTES;

D O I：

10.1007/BF01741344

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this study was to determine immunological parameters in the peripheral blood that correlate with the clinical effect of interleukin-2 (IL-2) in patients with metastatic renal cell cancer. A group of 26 patients with metastatic renal cell cancer underwent IL-2 treatment using a 36-day schedule with continuous intravenous IL-2 infusion (3 x 10(6) units m-2 day-1) administered from days 1 to 5 and days 12 to 16. The white blood cell count and the absolute and relative number of neutrophils, lymphocytes, eosinophils and monocytes were recorded six times in peripheral blood during the treatment. Also the blood counts of T cell and NK cell subsets and cells expressing the T cell activation markers IL-2R-alpha and VLA-1 were measured. The lymphokine-activated killer (LAK) cell cytotoxicity was measured either with or without additional in vitro stimulation by IL-2. Multivariate statistical analysis showed that the clinical responses were related to the administered dose of IL-2, to a low number of blood cells expressing IL-2 receptors and to a reduction in the blood monocyte count (P < 0.05).

引用

页码：111 / 114

页数：4

共 23 条

[1]

Afifi A.A., 1984, COMPUTER AIDED MULTI

[2]

BOLDT DH, 1988, CANCER RES, V48, P4409

[3]

BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77

[4] ESTABLISHED CELL LINE OF URINARY-BLADDER CARCINOMA (T-24) CONTAINING TUMOR-SPECIFIC ANTIGEN [J].

BUBENIK, J ;

BARESOVA, M ;

VIKLICKY, V ;

JAKOUBKOVA, J ;

SAINEROVA, H ;

DONNER, J .

INTERNATIONAL JOURNAL OF CANCER, 1973, 11 (03) :765-773

[5]

CHRISTENSEN B, 1984, ANTICANCER RES, V4, P319

[6]

COHEN PJ, 1987, AM J PATHOL, V129, P208

[7]

DIMITRIUBONA A, 1983, J IMMUNOL, V130, P145

[8]

ETTINGHAUSEN SE, 1987, BLOOD, V69, P1654

[9]

FAVROT MC, 1990, J BIOL RESP MODIF, V9, P167

[10] ADDITION OF INTERLEUKIN-2 INVITRO AUGMENTS DETECTION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY GENERATED INVIVO [J].

HANK, JA ;

WEILHILLMAN, G ;

SURFUS, JE ;

SOSMAN, JA ;

SONDEL, PM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (01) :53-59

← 1 2 3 →